Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 7/20 | 1.00 |
| ▸ | ESR1 | P03372 | 9/20 | 0.77 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | HTR6 | P50406 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | GBA1 | P04062 | 1/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | PRKCG | P05129 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | PRKCB | P05771 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL638891 | 1.00 | ESRRB (1.00) | ESRRBESR1ESR2MAPTHTR6 | |
| SCHEMBL638890 | 1.00 | ESRRB (1.00) | ESRRBESR1ESR2MAPTHTR6 | |
| SCHEMBL10016281 | 0.93 | ESRRB (0.88) | ESRRBESR1ESR2MAPTHTR6 | |
| SCHEMBL10047996 | 0.87 | ESRRB (1.00) | ESRRBESR1ESR2MAPTMEN1 | |
| SCHEMBL10016265 | 0.87 | ESRRB (1.00) | ESRRBESR1ESR2MAPTMEN1 | |
| SCHEMBL640131 | 0.84 | ESR1 (0.81) | ESRRBESR1ESR2MAPTHTR6 | |
| SCHEMBL640130 | 0.84 | ESR1 (0.81) | ESRRBESR1ESR2MAPTHTR6 | |
| SCHEMBL640132 | 0.84 | ESR1 (0.81) | ESRRBESR1ESR2MAPTHTR6 | |
| SCHEMBL936134 | 0.83 | ESRRB (0.75) | ESRRBESR1ESR2MAPTHTR6 | |
| SCHEMBL7598659 | 0.79 | ESR1 (0.69) | ESRRBESR1ESR2MAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590056-B2 | ERR modulators and uses thereof | CITY OF HOPE (US) | 2020-03-17 | — | — | US | disclosed |
| US-20180297923-A1 | ERR MODULATORS AND USES THEREOF | CITY OF HOPE | 2018-10-18 | — | — | US | disclosed |
| US-8119695-B2 | Compounds and methods for treating breast cancer and other diseases | CITY OF HOPE (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119695-B2 | Compounds and methods for treating breast cancer and other diseases | CITY OF HOPE (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090176305-A1 | COMPOUNDS AND METHODS FOR TREATING BREAST CANCER AND OTHER DISEASES | CITY OF HOPE | 2009-07-09 | — | — | US | disclosed |
| US-20090176305-A1 | COMPOUNDS AND METHODS FOR TREATING BREAST CANCER AND OTHER DISEASES | CITY OF HOPE | 2009-07-09 | — | — | US | disclosed |
| US-7531578-B2 | Acetic acid 4-{1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester; estrogen related receptor (ERR beta or ERR gamma) antagonist; thirty times more effective than 4-hydroxytamoxifen | CITY OF HOPE (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531578-B2 | Acetic acid 4-{1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester; estrogen related receptor (ERR beta or ERR gamma) antagonist; thirty times more effective than 4-hydroxytamoxifen | CITY OF HOPE (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531578-B2 | Acetic acid 4-{1-[4-(2-dimethylamino-ethoxy)-phenyl]-2-phenyl-but-1-enyl}-phenyl ester; estrogen related receptor (ERR beta or ERR gamma) antagonist; thirty times more effective than 4-hydroxytamoxifen | CITY OF HOPE (US) | 2009-05-12 | — | — | US | disclosed |
| US-20050096384-A1 | Compounds and methods for treating breast cancer and other diseases | CITY OF HOPE | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297923-A1 | ERR MODULATORS AND USES THEREOF | ESRRA, ESRRB, ESRRG | ESRRB 2/4885ESR1 43/4885ESR2 7/4885 |
| US-10590056-B2 | ERR modulators and uses thereof | ESRRA, ESRRB, ESRRG | ESRRB 2/4885ESR1 43/4885ESR2 7/4885 |
| US-20050096384-A1 | Compounds and methods for treating breast cancer and other diseases | ESRRB, ESRRG, ESRRA | ESRRB 1/4885ESR1 7/4885ESR2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.